# US 11,028,165 B2 · Nucleic acid encoding anti-GM-CSF antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,028,165 B2
- Document ID: US11028165B2
- Status: Granted
- Kind: B2
- Application number: 16/442,779
- Filed: 2019-06-17
- Published: 2020-01-23
- Granted: 2021-06-08
- Earliest claimed: 2005-05-18
- Assignees: Morphosys AG
- Applicants: Morphosys AG
- Inventors: Stefan Steidl; Elisabeth Thomassen-Wolf
- Web page: https://patentgrep.com/patent/US11028165B2

## CPC

- C07K 16/243: {Colony Stimulating Factors}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61K 2039/505: {comprising antibodies}
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C07K 2317/21: from primates, e.g. man
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, inflammatory diseases such as rheumatoid arthritis. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of GM-CSF in the progression of various disorders. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.

## Claims

### Claim 1

An isolated nucleic acid sequence that encodes a Granulocyte-macrophage colony stimulating factor (GM-CSF) binding protein, wherein the GM-CSF binding protein is specific for human GM-CSF, and wherein the GM-CSF binding protein comprises:
(a) a VH region comprising a sequence at least 95% identical to the sequence of SEQ ID NO:20; and/or
(b) a VL region comprising a sequence at least 95% identical to the sequence of SEQ ID NO:40.

### Claim 2 (depends on 1)

The isolated nucleic acid sequence according to claim 1, wherein the GM-CSF binding protein comprises a synthetic polypeptide, a humanised sequence, or a chimeric sequence.

### Claim 3 (depends on 1)

A vector comprising the isolated nucleic acid sequence according to claim 1.

### Claim 4 (depends on 3)

An isolated cell comprising the vector according to claim 3.

### Claim 5 (depends on 4)

The cell according to claim 4, wherein the cell is bacterial.

### Claim 6 (depends on 4)

The cell according to claim 4, wherein the cell is eukaryotic.

### Claim 7 (depends on 1)

The isolated nucleic acid sequence according to claim 1, wherein the GM-CSF binding protein comprises a VH region comprising a sequence according to SEQ ID NO:20; and a VL region comprising a sequence according to SEQ ID NO:40.

### Claim 8 (depends on 1)

The isolated nucleic acid sequence according to claim 1, wherein the GM-CSF binding protein comprises an HCDR1, HCDR2 and HCDR3 sequence of SEQ ID NO: 20, and an LCDR1, LCDR2 and LCDR3 sequence of SEQ ID NO: 40.

### Claim 9 (depends on 7)

A vector comprising the isolated nucleic acid sequence according to claim 7.

### Claim 10 (depends on 9)

An isolated cell comprising the vector according to claim 9.

### Claim 11 (depends on 10)

The isolated cell according to claim 10, wherein the cell is bacterial.

### Claim 12 (depends on 10)

The isolated cell according to claim 10, wherein the cell is eukaryotic.

### Claim 13 (depends on 1)

The isolated nucleic acid sequence according to claim 1, wherein the GM-CSF binding protein comprises an HCDR1, HCDR2 and HCDR3 sequence of SEQ ID NO: 20.

### Claim 14 (depends on 1)

The isolated nucleic acid sequence according to claim 1, wherein the GM-CSF binding protein comprises a LCDR1, LCDR2 and LCDR3 sequence of SEQ ID NO: 40.